Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given signed consent to take part and are able to follow the study requirements.
- People aged 18 or older but under 75 years old at the time of signing the consent form.
- People who have a laboratory-confirmed diagnosis of triple-negative breast cancer (TNBC), based on specific test results showing low or absent levels of certain receptors (ER, PR, and HER2).
- People whose TNBC has continued to grow or has come back during or after systemic (whole-body) treatment.
- People who have received at least one round of systemic treatment for advanced or metastatic TNBC, or whose cancer came back or worsened either during or within 6 months of finishing post-surgery chemotherapy.
- People whose tumor cells have been confirmed to show expression of a protein called AXL, based on a laboratory tissue test.
- People who can provide tumor tissue samples — both a recent sample (taken after the most recent cancer progression or relapse) and, if available, an older archived sample from before that progression.
- People who have at least one measurable tumor that can be assessed using standard imaging criteria (RECIST 1.1).
- People with a functional status score of 0 or 1 on the ECOG scale, meaning they are fully active or able to carry out light activity (confirm with trial site).
- People who, in the trial doctor's opinion, have a life expectancy of at least 4 months from the time of signing the consent form.
Who may not be able to join:
- People for whom a curative surgery or full-course radiotherapy is considered appropriate, unless it is minor surgery or palliative (comfort-focused) radiation.
- People with currently active cancer spread to the brain or the lining of the brain and spinal cord. People with previously treated brain metastases may still be considered if the metastases were treated with surgery or radiation, have been stable for at least 4 weeks before joining the study (meaning no neurological symptoms, no need for steroid medications, and no individual lesion larger than 1.5 cm), and show no signs of new or worsening brain involvement. People newly found to have brain metastases during the screening period are not eligible.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Arina V Zinkina-Orikhan, PhD, Director of Clinical Development Department, BIOCAD
Phone: +7 911 081 23 68
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.